PFKFB3 and peripheral arterial disease: In summary, we hypothesize that XFZYC acts by modulating glycolytic metabolism in endothelial cells, with a primary focus on regulating the critical target PFKFB3, thereby alleviating ischemia-related symptoms in PAD.